THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT
Background: Maintenance of stable glycemic control is an important prerequisite of effective treatment of patients with type 1 diabetes mellitus (DM). The ultra-long-acting basal insulin degludec allows for reduction of glycemic variability and for a substantial reduction in the rates of hypoglycemi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
MONIKI
2016-12-01
|
| Series: | Alʹmanah Kliničeskoj Mediciny |
| Subjects: | |
| Online Access: | https://www.almclinmed.ru/jour/article/view/428 |
| _version_ | 1818886841039847424 |
|---|---|
| author | M. F. Kalashnikova D. R. Yazykova N. V. Likhodey A. V. Zilov Yu. P. Sych E. S. Maloletkina V. V. Fadeev |
| author_facet | M. F. Kalashnikova D. R. Yazykova N. V. Likhodey A. V. Zilov Yu. P. Sych E. S. Maloletkina V. V. Fadeev |
| author_sort | M. F. Kalashnikova |
| collection | DOAJ |
| description | Background: Maintenance of stable glycemic control is an important prerequisite of effective treatment of patients with type 1 diabetes mellitus (DM). The ultra-long-acting basal insulin degludec allows for reduction of glycemic variability and for a substantial reduction in the rates of hypoglycemia with equivalent glycemic control. Evaluation of the impact of this novel insulin on diabetes-dependent quality of life and patient satisfactions with the treatment is necessary for comprehensive assessment of treatment efficacy.Aim: To study changes of glycated hemoglobin (HbA1c), rates of hypoglycemia, diabetes-dependent quality of life and treatment satisfaction in patients with type 1 DM, who have been switched to insulin degludec.Materials and methods: This open 12-week observational comparative study included 25 patients with type 1 DM (median age, 36 [20; 63] years), who were switched to insulin degludec in combination with a ultra-short insulin analogue. The control group included 21 patients with type 1 DM (median age, 40 [23; 63] years), who continued their treatment with a long-acting insulin analogue glargine. At baseline and at week 12 after switching to insulin degludec, we assessed HbA1c level, mean insulin dose, depression score, diabetes-dependent quality of life and patient satisfaction with the treatment with the use of the Russian versions of the diabetes-specific questionnaires “Audit of Diabetes-Dependent Quality of life” (RuADDQoL), and “Diabetes Treatment Satisfaction Questionnaire” (DTSQ), respectively.Results: At 3 months, there was a significant reduction of the HbA1c levels in the main and the control groups to 7.57% (Ме 7.5 [7.1; 8.4]; р=0.03) and 8.18% (Ме 7.8% [7.4; 8.7]; р=0.04), respectively. The mean reduction of this parameter under treatment with degludec was slightly higher than under treatment with glargine (0.73 vs 0.57%, respectively), at 3 months the difference being statistically significant (p=0.034). To achieve an equivalent glycemic control, the mean daily dose of insulin degludec was reduced by 26%. Switching to insulin degludec was associated with a significant reduction in non-severe hypoglycemia rates by 45% (р<0.001). In the main group, there was an improvement of the mean total weighted score of Ru-ADDQoL from -2.2 (Ме -1.28 [-2; -0.86]) at baseline to -1.5 (Ме -1.28 [-2; -0.86]) at 12 week, with positive changes in the most domains, demonstrating the improvement of quality of life In the reference group, the mean total weighted Ru-ADDQoL score at 3 months increased 0.4 (Me 0.1 [-0.56; -1] to -1.51 (Me -1.23 [-2; -1]). In the glargine group there were no significant changes on any of the Ru-ADDQoL domains. There was a significant improvement in the patients satisfaction with treatment in the degludec group, with an increase of the average DTSQ score by 5 in 3 months of therapy.Conclusion: Based on the results of this short-term observational study, the following conclusion can be drawn: treatment with insulin degludec in type 1 DM is as effective as treatment with insulin glargine; however, it allows for reduction of the mild hypoglycemia rates by 45%. Therefore, this insulin can be recommended, first of all, to those type 1 DM patients who demonstrate substantial glycemic fluctuations, frequent hypoglycemia, hypoglycemic unawareness or who do not achieve the glycemic goals of treatment. Finally, this would lead to better health-related quality of life and more treatment satisfaction. |
| first_indexed | 2024-12-19T16:27:44Z |
| format | Article |
| id | doaj.art-33f64098aa874ec1889f5d6264076b6a |
| institution | Directory Open Access Journal |
| issn | 2072-0505 2587-9294 |
| language | Russian |
| last_indexed | 2024-12-19T16:27:44Z |
| publishDate | 2016-12-01 |
| publisher | MONIKI |
| record_format | Article |
| series | Alʹmanah Kliničeskoj Mediciny |
| spelling | doaj.art-33f64098aa874ec1889f5d6264076b6a2022-12-21T20:14:17ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942016-12-0144439240510.18786/2072-0505-2016-44-4-392-405387THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENTM. F. Kalashnikova0D. R. Yazykova1N. V. Likhodey2A. V. Zilov3Yu. P. Sych4E. S. Maloletkina5V. V. Fadeev6I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityBackground: Maintenance of stable glycemic control is an important prerequisite of effective treatment of patients with type 1 diabetes mellitus (DM). The ultra-long-acting basal insulin degludec allows for reduction of glycemic variability and for a substantial reduction in the rates of hypoglycemia with equivalent glycemic control. Evaluation of the impact of this novel insulin on diabetes-dependent quality of life and patient satisfactions with the treatment is necessary for comprehensive assessment of treatment efficacy.Aim: To study changes of glycated hemoglobin (HbA1c), rates of hypoglycemia, diabetes-dependent quality of life and treatment satisfaction in patients with type 1 DM, who have been switched to insulin degludec.Materials and methods: This open 12-week observational comparative study included 25 patients with type 1 DM (median age, 36 [20; 63] years), who were switched to insulin degludec in combination with a ultra-short insulin analogue. The control group included 21 patients with type 1 DM (median age, 40 [23; 63] years), who continued their treatment with a long-acting insulin analogue glargine. At baseline and at week 12 after switching to insulin degludec, we assessed HbA1c level, mean insulin dose, depression score, diabetes-dependent quality of life and patient satisfaction with the treatment with the use of the Russian versions of the diabetes-specific questionnaires “Audit of Diabetes-Dependent Quality of life” (RuADDQoL), and “Diabetes Treatment Satisfaction Questionnaire” (DTSQ), respectively.Results: At 3 months, there was a significant reduction of the HbA1c levels in the main and the control groups to 7.57% (Ме 7.5 [7.1; 8.4]; р=0.03) and 8.18% (Ме 7.8% [7.4; 8.7]; р=0.04), respectively. The mean reduction of this parameter under treatment with degludec was slightly higher than under treatment with glargine (0.73 vs 0.57%, respectively), at 3 months the difference being statistically significant (p=0.034). To achieve an equivalent glycemic control, the mean daily dose of insulin degludec was reduced by 26%. Switching to insulin degludec was associated with a significant reduction in non-severe hypoglycemia rates by 45% (р<0.001). In the main group, there was an improvement of the mean total weighted score of Ru-ADDQoL from -2.2 (Ме -1.28 [-2; -0.86]) at baseline to -1.5 (Ме -1.28 [-2; -0.86]) at 12 week, with positive changes in the most domains, demonstrating the improvement of quality of life In the reference group, the mean total weighted Ru-ADDQoL score at 3 months increased 0.4 (Me 0.1 [-0.56; -1] to -1.51 (Me -1.23 [-2; -1]). In the glargine group there were no significant changes on any of the Ru-ADDQoL domains. There was a significant improvement in the patients satisfaction with treatment in the degludec group, with an increase of the average DTSQ score by 5 in 3 months of therapy.Conclusion: Based on the results of this short-term observational study, the following conclusion can be drawn: treatment with insulin degludec in type 1 DM is as effective as treatment with insulin glargine; however, it allows for reduction of the mild hypoglycemia rates by 45%. Therefore, this insulin can be recommended, first of all, to those type 1 DM patients who demonstrate substantial glycemic fluctuations, frequent hypoglycemia, hypoglycemic unawareness or who do not achieve the glycemic goals of treatment. Finally, this would lead to better health-related quality of life and more treatment satisfaction.https://www.almclinmed.ru/jour/article/view/428insulin degludecglycemic controltype 1 diabetes mellitusquality of lifesatisfaction with treatment |
| spellingShingle | M. F. Kalashnikova D. R. Yazykova N. V. Likhodey A. V. Zilov Yu. P. Sych E. S. Maloletkina V. V. Fadeev THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT Alʹmanah Kliničeskoj Mediciny insulin degludec glycemic control type 1 diabetes mellitus quality of life satisfaction with treatment |
| title | THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT |
| title_full | THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT |
| title_fullStr | THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT |
| title_full_unstemmed | THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT |
| title_short | THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT |
| title_sort | use of ultra long acting insulin analogue degludec in type 1 diabetes mellitus in clinical practice the influence on quality of life and satisfaction with treatment |
| topic | insulin degludec glycemic control type 1 diabetes mellitus quality of life satisfaction with treatment |
| url | https://www.almclinmed.ru/jour/article/view/428 |
| work_keys_str_mv | AT mfkalashnikova theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT dryazykova theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT nvlikhodey theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT avzilov theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT yupsych theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT esmaloletkina theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT vvfadeev theuseofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT mfkalashnikova useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT dryazykova useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT nvlikhodey useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT avzilov useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT yupsych useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT esmaloletkina useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment AT vvfadeev useofultralongactinginsulinanaloguedegludecintype1diabetesmellitusinclinicalpracticetheinfluenceonqualityoflifeandsatisfactionwithtreatment |